AeroVironment

▲ Bull Case

• ◆Switchblade is the de facto NATO loitering-munition standard with 100,000+ Ukraine combat deployments and 2–3 year production lead vs. Anduril. Global loitering-munition TAM expands from ~$1.5B (2025) to $4–6B (2030) at 25%+ CAGR. AVAV can achieve $1B+ standalone Switchblade revenue by FY28.
• ◆Backlog at record $1.1B (52% YoY growth) with 1.6x book-to-bill provides 1.5–2.5 years revenue visibility. DepSecDef 'Replicator' initiative ($1B+ funding for attritable autonomous systems) directly benefits AVAV's loitering-munitions and small-UAS portfolio. NATO's 2%→3–4% defense-spending commitments create structural multi-year tailwind through 2028.
• ◆BlueHalo combination creates U.S. mid-cap's most complete layered counter-UAS portfolio: RF detect/defeat (Titan family), kinetic interceptor (Freedom Eagle FE-1), directed-energy laser (Locust LWS), and electronic warfare. Global C-UAS TAM trebles by 2030 ($3B → $10–15B at 30%+ CAGR). AVAV positioned to lead across all three modalities.

▼ Bear Case

• ◆Q3 FY26 revenue miss ($408M vs. $483M consensus) + $150M guidance cut + $151M BADGER SCAR impairment signal execution credibility collapse that may persist 2–3 quarters. This is third goodwill impairment in four years. Pattern of overpaying for M&A targets relative to execution now embedded. If Q4 FY26 or FY27 guidance misses again, stock resets to $150–190.
• ◆Ukraine revenue (estimated 12–18% of FY26 mix) at structural risk if U.S. aid policies shift or Russia/Ukraine reach settlement. 30% haircut on Ukraine orders would reduce FY27 revenue guidance by $100–150M. When combined with DOGE-led Pentagon review pressure, FY27 defense budget growth cannot be taken for granted.
• ◆Arlington Capital's 39.5% secondary-distribution window opens Q4 2026 / Q1 2027. If Arlington faces fund-level liquidity pressures or decides to exit, 5–10% concentrated secondary offering could press stock toward $170–190 on technical overhang alone.

“Bull consensus (16–21 analysts, Strong Buy, mean PT $305–317) assumes Q3 FY26 is a one-off, BlueHalo integration completes on plan with no further impairments, FY27 guidance reaffirms Street consensus of $2.4–2.6B with 15–16% margins, and Replicator funding sustains through 2028. Variant view (held by execution-focused investors) argues Q3 FY26 is not a one-off but first manifestation of 2–3 quarter reset cycle requiring three in-line quarters (June, September, December 2026) to rebuild management credibility. This view emphasizes Arlington Capital secondary distribution will create overhang beginning Q4 2026 / Q1 2027 and DOGE-led Pentagon review will cascade to AVAV's backlog, resetting FY27 guidance lower. Unresolved tension: Bull side underestimates magnitude of near-term execution risk and credibility reset (2–3 quarters, not 1). Variant side underestimates durability of $1.1B backlog and structural tailwind from Switchblade adoption, Replicator funding, and C-UAS category expansion.”

• ◆Q4 FY26 Earnings + FY27 Guidance (June 2026): CRITICAL. Reaffirmation of $1.85–1.95B FY26 and $2.4B+ FY27 guidance recovers credibility and re-rates stock to $240–260. Guidance cut below $2.3B resets to $160–180.
• ◆FY27 NDAA Appropriations (September 2026): Replicator and counter-UAS funding levels are decisive. $500M+ incremental Replicator funding and robust C-UAS provisions close bull case. DOGE-led cuts hitting strategic programs trigger downside case.
• ◆Arlington Capital Lock-Up Expiry & Secondary Distribution (Q4 2026 / Q1 2027): 39.5% stake is material. Orderly 6–12 month distribution manageable; aggressive 5–10% float secondary creates 10–15% overhang pressure.
• ◆BlueHalo Material Weakness Internal Controls Remediation (Ongoing through 2027): 10-K disclosures June 2026 (FY26) and June 2027 (FY27) signal progress. Further impairments trigger multiple compression and downside revision.
• ◆Anduril Production Scale Announcements (Quarterly): Bolt-M production exceeding 500 units/year or major NATO/Indo-Pacific design win questions AVAV's moat durability and competitive positioning.

• ◆Q4 FY26 + FY27 Guidance Misses (Multi-quarter Reset): HIGH severity, MEDIUM probability (40%). Revenue <$540M Q4 or FY27 guide <$2.3B resets stock to $150–180 (–28% to –14%). Thesis reset required.
• ◆Arlington Capital Secondary Distribution (Forced Selling): HIGH severity, MEDIUM probability (50%). Liquidity pressures or fund timeline could trigger aggressive distribution, pressing stock to $170–190 (–18% to –9%) on technical overhang.
• ◆DOGE Pentagon Budget Cuts Cascading to AVAV Programs: HIGH severity, MEDIUM probability (35%). BADGER SCAR stop-work is proof-of-concept; Switchblade, Replicator, C-UAS programs at risk if cuts broaden. Could reset stock to $120–150 (–42% to –28%).
• ◆Further BlueHalo Impairments (WASP, Locust, Space Programs): MEDIUM severity, LOW-MEDIUM probability (25%). FY27/FY28 write-downs on Space/Directed Energy repeat pattern and reset stock to $120–150 (–42% to –28%).
• ◆Anduril Competitive Escalation (Design Win or Production Ramp): MEDIUM severity, LOW-MEDIUM probability (30%). Major NATO or Indo-Pacific LMS/SUAS contract win questions Switchblade moat durability, resetting stock to $170–190 (–18% to –9%).